Danaher Corporation (DHR)
Danaher Rides on Strength in Biotechnology Segment: Will It Sustain?
DHR's Biotechnology segment grows as China demand, bioprocessing and improving discovery markets offset regional headwinds.
Can Danaher (DHR) Climb 32.39% to Reach the Level Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 32.4% in Danaher (DHR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Don't Quit on Danaher Stock After Horrific Earnings Reaction
There's reason to believe the stock can stage a comeback after its worst day in two decades.
Danaher Q2 Earnings Beat Estimates, Life Sciences Sales Up Y/Y
DHR beats Q2 estimates as Life Sciences posts its strongest quarter in years, prompting the company to raise its 2026 adjusted EPS outlook.
Danaher Corporation (DHR) Q2 2026 Earnings Call Transcript
Danaher Corporation (DHR) Q2 2026 Earnings Call Transcript
Compared to Estimates, Danaher (DHR) Q2 Earnings: A Look at Key Metrics
The headline numbers for Danaher (DHR) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Danaher Q2 Earnings Call Highlights
Danaher NYSE: DHR reported better-than-expected second-quarter 2026 results, with management citing accelerating core revenue growth, stronger life sciences demand and benefits from productivity initiatives, while also addressing investor concerns over delayed bioprocessing shipments.
Danaher (DHR) Q2 Earnings and Revenues Top Estimates
Danaher (DHR) came out with quarterly earnings of $1.94 per share, beating the Zacks Consensus Estimate of $1.84 per share. This compares to earnings of $1.8 per share a year ago.
Will Danaher (DHR) Beat Estimates Again in Its Next Earnings Report?
Danaher (DHR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Danaher Gears Up to Post Q2 Earnings: Is a Beat in the Offing?
DHR heads into Q2 earnings with bioprocessing and diagnostics strength, but rising costs and debt could pressure profitability.
Countdown to Danaher (DHR) Q2 Earnings: A Look at Estimates Beyond Revenue and EPS
Besides Wall Street's top-and-bottom-line estimates for Danaher (DHR), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2026.
Implied Volatility Surging for Danaher Stock Options
Investors need to pay close attention to DHR stock based on the movements in the options market lately.
